Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow VOLITIONRX LTD

Get SEC filing alerts via email and in your feed for VOLITIONRX LTD

VNRX

VOLITIONRX LTD

About VOLITIONRX LTD

VolitionRx Limited is a multinational epigenetics company developing simple, cost-effective blood tests for early detection and monitoring of diseases such as cancer and sepsis in humans and animals. Its proprietary technologies analyze circulating nucleosomes and chromatin structures to enable non-invasive diagnostics, with applications spanning veterinary and human healthcare markets. The company focuses on innovative assay development, licensing IP, and strategic partnerships to improve disease management worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from VOLITIONRX LTD

1
1
VOLITIONRX LTD VolitionRx Reports Q1 2026 Revenue Growth to $985,076, Driven by Product Sales

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
VOLITIONRX LTD VolitionRx Reports 40% Revenue Growth to $1.73 Million Amid Ongoing Losses

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
VOLITIONRX LTD VolitionRx Reports 23% Revenue Growth to $1.28 Million, Faces Ongoing Operating Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
VOLITIONRX LTD VolitionRx Reports 15% Revenue Growth and $11.8 Million Net Loss for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
VOLITIONRX LTD VolitionRx Reports 44% Revenue Growth in Q1 2025, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
VOLITIONRX LTD VolitionRx Reports 59% Revenue Growth to $1.23 Million for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
VOLITIONRX LTD VolitionRx Reports Significant Revenue Growth, Reduced Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments